Skip to main content

Table 2 Correlation between PD-L1 expression and clinicopathological features

From: Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis

Clinical characteristics Number of studies Cases Odds ratio (95% CI) P Heterogeneity
I2 (%) P
Gender (male/female) 11 2390 1.09 (0.78, 1.51) 0.62 21 0.24
Age (older/younger) 8 1535 0.93 (0.73, 1.19) 0.58 0 0.92
Hepatitis (yes/no) 8 1799 0.68 (0.47, 0.98) 0.04 5 0.40
Cirrhosis (yes/no) 6 999 1.12 (0.74, 1.70) 0.59 30 0.20
AFP (higher/lower) 8 1432 1.43 (1.02, 2.00) 0.04 35 0.14
Tumour size (larger/smaller) 8 1688 1.30 (0.88, 1.92) 0.19 55 0.03
Tumour encapsulation (no/yes) 4 933 0.91 (0.47, 1.77) 0.79 68 0.03
Tumour number (multiple/single) 8 1731 1.05 (0.75, 1.49) 0.77 31 0.18
Vascular invasion (yes/no) 9 2050 1.62 (0.99, 2.64) 0.06 75 < 0.001
TNM stage (advanced/earlier) 11 2169 1.04 (0.73, 1.50) 0.81 42 0.07
  1. AFP alpha-fetoprotein, CI confidence interval, PD-L1 programmed death ligand 1, TNM tumour-node-metastasis
  2. The italic P value refers to P < 0.05